Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability

Author:

Rahman Md. Shafikur1,Kumari Shikha1,Esfahani Shiva Hadi2,Nozohouri Saeideh2,Jayaraman Srinidhi2,Kinarivala Nihar2ORCID,Kocot Joanna2,Baez Andrew2,Farris Delaney2,Abbruscato Thomas J.23,Karamyan Vardan T.23ORCID,Trippier Paul C.145ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

2. Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United States

3. Center for Blood Brain Barrier Research, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, United States

4. Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

5. UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

Funder

National Institute of Neurological Disorders and Stroke

University of Nebraska Medical Center

Health Sciences Center, Texas Tech University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3